The Right to FDA‑Approved Medicines Act establishes a statutory right for individuals to obtain FDA‑approved drugs and for health care providers to prescribe, provide information about, and refer patients for those medicines. It bars government actions that single out such medicines, providers, or facilities and sets a high evidentiary standard for any law claimed to justify such a limitation.
The bill reaches federal, state, and local law, applies retroactively to existing rules, and authorizes both the U.S. Attorney General and private parties to sue to block restrictions; courts must award costs and attorneys’ fees to prevailing plaintiffs. The measure preserves FDA’s approval authority and explicitly does not compel insurers to cover particular benefits, but its preemption language and waiver of state immunity make it a powerful tool to challenge state regulation of drug access.
At a Glance
What It Does
Recognizes a statutory right for people to obtain FDA‑approved medicines and for licensed providers to furnish those medicines and related information, referrals, and services. It prohibits government limits that single out such medicines, providers, or facilities and requires the government to meet a clear‑and‑convincing standard to justify any restriction.
Who It Affects
Physicians, nurse practitioners, pharmacists, telehealth platforms, clinics, drug manufacturers, state and local regulators, and patients—particularly those in jurisdictions that currently restrict access to specific FDA‑approved drugs. State legislatures and licensing boards are primary targets of the bill’s preemption and enforcement provisions.
Why It Matters
The bill preempts existing and future state laws that impede access to FDA‑approved medicines, authorizes aggressive enforcement (including private suits with fee shifting), and waives state immunity—meaning many state restrictions could be rapidly litigated and overturned. For compliance officers and health systems, the bill replaces regulatory uncertainty with litigation risk and a new federal standard.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act defines “FDA‑approved medicines” to include drugs approved under section 505 of the Federal Food, Drug, and Cosmetic Act and biologics licensed under section 351 of the Public Health Service Act, and it uses a broad definition of health care provider that explicitly includes pharmacists and mid‑level practitioners. The statutory right covers not only prescribing and dispensing but also information, referrals, and related services, so communications and telehealth workflows are within the law’s reach.
Central to the bill is the prohibition on governmental measures that “expressly, effectively, implicitly, or as‑implemented” single out FDA‑approved medicines, providers who offer them, or facilities where they are provided. That language is written to catch narrowly targeted state actions—laws, orders, or administrative policies that treat certain drugs or the clinicians who supply them differently than other therapies.
The Act also says rights must be free from coercion, signaling that the protection extends beyond mere authorization and into practices that could make access impracticable.The statute builds in a defense mechanism for governments but sets a demanding burden: to defend a restriction, the government must prove by clear and convincing evidence that the limitation significantly advances access to FDA‑approved medicines and that no less‑restrictive alternative could achieve the same end. The bill also makes clear that this measure does not curtail FDA’s authority to approve or license drugs, leaving FDA’s safety and efficacy role intact.Finally, the Act is written to be broadly enforceable.
It preempts state and federal laws that conflict with its protections, applies to laws enacted before or after it takes effect, and includes a private right of action and Attorney General enforcement. Courts are directed to set aside violating measures, award equitable relief, and grant costs and attorneys’ fees to prevailing plaintiffs; plaintiffs do not need to exhaust administrative remedies first.
The Act takes effect immediately on enactment, which both accelerates challenges and raises predictable questions about ongoing state enforcement and licensing practices.
The Five Things You Need to Know
The bill defines “FDA‑approved medicine” to include approvals under FDCA §505 and licensure under PHSA §351, covering both drugs and biologics.
It creates a statutory right for individuals to obtain FDA‑approved medicines and for health care providers to provide those medicines plus related information, referrals, and services, and it bars coercive restrictions.
Governments may not enact or enforce measures that single out medicines, providers, or facilities; to defend such a measure a government must prove by clear and convincing evidence that the restriction significantly advances access and that no less‑restrictive alternative exists.
The Act preempts state and federal laws that conflict with its protections, applies retroactively and prospectively, and explicitly states it applies notwithstanding RFRA.
It authorizes both the U.S. Attorney General and private parties (including providers and patients) to sue, permits injunctive relief, requires payment of costs and attorneys’ fees to prevailing plaintiffs, and waives certain state immunity defenses.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Names the measure the “Right to FDA‑Approved Medicines Act.” This is standard but signals the bill’s framing: emphasis on statutory rights tied to FDA approval rather than state policy choices.
Definitions — scope of covered products and actors
Specifies that covered products include drugs approved under FDCA §505 and biologics licensed under PHSA §351, so both small‑molecule drugs and licensed biologics are in scope. The health care provider definition is broad—explicitly listing physicians, nurse‑midwives, nurse practitioners, physician assistants, and pharmacists—and the government definition expressly includes state and local entities, which expands the Act’s reach into local licensing and enforcement actions.
Statutory right to obtain and provide medicines, information, and referrals
Creates the core entitlement: individuals may obtain FDA‑approved medicines free from coercion and providers may offer medicines and related information, referrals, and services. The provision prohibits limits that ‘single out’ medicines, providers, or facilities and thus targets laws that are tailored to block access to specific therapies. Practical effect: clinic policies, telehealth rules, pharmacy practices, and targeted criminal or administrative statutes are all potential subjects of challenge.
Exception with heightened burden for restrictions
Allows a defendant government to justify a restriction only by meeting a clear‑and‑convincing evidence standard that the restriction significantly advances access and that no less‑restrictive alternative exists. This is a high evidentiary bar—higher than preponderance—and shifts the litigation dynamic, forcing governments to produce robust proof of both effectiveness and lack of alternatives.
Preemption, applicability, and coverage carve‑out
Preempts conflicting federal, state, and local laws and applies to laws enacted before or after the Act. It expressly defeats defenses like RFRA and abrogates certain state immunity protections for covered actions. The section also clarifies that the Act does not require group health plans or federal program coverage for particular benefits, so it does not itself create an insurance‑payment mandate even while it protects access rights.
Enforcement, remedies, and fee shifting
Authorizes the Attorney General to sue states or government officials and creates a broad private right of action for affected individuals and entities, including providers and patients. Courts must be able to set aside violating measures and may grant injunctive relief; prevailing plaintiffs are entitled to costs and reasonable attorney’s fees and need not exhaust administrative remedies. The section also removes certain Eleventh and Tenth Amendment immunity defenses for officials and states implementing violating restrictions.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients in states with restrictive laws: Individuals seeking FDA‑approved therapies that are currently subject to state bans or targeted restrictions will gain a federal cause of action to challenge those constraints and to obtain injunctive relief.
- Front‑line clinicians and pharmacists: Providers who prescribe, dispense, or counsel about FDA‑approved medicines will have statutory protection to provide medicines, referrals, and information without fear of targeted state penalties or licensing actions.
- Telehealth companies and cross‑state prescribers: Firms that enable remote prescribing or interstate delivery of medicines stand to benefit because the Act’s scope includes informational and referral services central to telemedicine models.
- Public‑interest litigants and advocacy organizations: The private right of action plus fee shifting makes it financially feasible for advocacy groups and impacted patients to bring challenges to state and local restrictions.
Who Bears the Cost
- State and local governments: Legislatures, health departments, and attorney generals face increased litigation exposure and the possibility of overturned statutes, regulations, or agency policies—plus fee awards to prevailing plaintiffs.
- State licensing and disciplinary boards: Boards that restrict provider practice related to specific drugs could see their orders enjoined and may incur legal defense costs and liability exposure.
- Health systems and facilities: Hospitals and clinics may need to revise policies, training, and compliance programs to avoid being treated as enforcing prohibited restrictions and could become parties to litigation.
- Courts and taxpayers: The combination of broad private enforcement, immediate effect, and fee shifting is likely to increase federal and state court dockets and create budgetary pressures associated with defense and potential fee awards.
Key Issues
The Core Tension
The central dilemma is balancing a federally enforceable individual right of access to FDA‑approved therapies against states’ authority to regulate medical practice and public health: the bill tilts enforcement power toward individuals and private plaintiffs, solving barriers to access but risking significant intrusions on state regulatory prerogatives and producing a litigation‑driven resolution for policy disputes.
The bill’s sweeping preemption clause and waiver of immunity create real federalism and implementation questions. By declaring that the Act applies to federal and state law enacted before or after it and that it applies notwithstanding RFRA, the text invites constitutional scrutiny over whether Congress has validly intruded on traditional state police powers to regulate medical practice and public health.
The “singles out” standard is fact‑sensitive: narrowly tailored public‑health measures aimed at specific products or settings (for example, targeted safety requirements) could be swept up, depending on how courts read the provision.
Enforcement mechanics intensify that risk. Fee shifting and an open private right of action are powerful tools for challengers and will incentivize litigation as the primary means of resolving regulatory disputes.
The Act does not solve the payment problem: it expressly declines to compel private or public insurers to cover specific medicines, so statutory access does not guarantee affordability. Practical questions remain about the reach of terms such as “information, referrals, and services” (does this include proactively shipping drugs across state lines?), the application to private actors acting under state licensing authority, and how courts will evaluate the clear‑and‑convincing standard in the context of regulatory policymaking.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.